Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Yunes Doleh"'
Publikováno v:
Cancer Medicine, Vol 9, Iss 10, Pp 3463-3476 (2020)
Abstract Background Pancreatic cancer represents the third leading cause of US cancer deaths, with median survival
Externí odkaz:
https://doaj.org/article/52a6b21e048645e38124e1d504d73b4a
Publikováno v:
Hepatic Oncology, Vol 7, Iss 3 (2020)
Aim: To describe the epidemiologic, humanistic and economic burdens of hepatocellular carcinoma (HCC) in the USA. Materials & methods: Studies describing the epidemiology and economic burden from national cohorts, any economic models, or any humanist
Externí odkaz:
https://doaj.org/article/a39f60d9a08a4d39aece90b4c0f282f0
Autor:
Elizabeth S Mearns, Diana M Sobieraj, C Michael White, Whitney J Saulsberry, Christine G Kohn, Yunes Doleh, Eric Zaccaro, Craig I Coleman
Publikováno v:
PLoS ONE, Vol 10, Iss 4, p e0125879 (2015)
When first line therapy with metformin is insufficient for patients with type 2 diabetes (T2D), the optimal adjunctive therapy is unclear. We assessed the efficacy and safety of adjunctive antidiabetic agents in patients with inadequately controlled
Externí odkaz:
https://doaj.org/article/85453ce88fd34f079efae474bf4d8d83
Autor:
Giovanni Antico, Elisabetta Malangone-Monaco, Michael J. Pishvaian, Yunes Doleh, Ashley L. Cole, Virginia Noxon
Publikováno v:
Pancreatology. 20:1434-1441
Background Objectives: Pancreatic cancer (PC) is a costly disease with a limited life-expectancy as it generally presents as an advanced, metastatic disease. Though current literature suggests cost varies by first line treatment, there is limited rea
Publikováno v:
Journal of Comparative Effectiveness Research. 9:945-957
Aim: To understand physician visit patterns among patients with stage IV (including nonmetastatic [M0] and metastatic [M1] disease) urothelial carcinoma (UC) and understand factors associated with a timely referral to a medical oncologist and systemi
Publikováno v:
Hepatic Oncology
Aim: To describe the epidemiologic, humanistic and economic burdens of hepatocellular carcinoma (HCC) in the USA. Materials & methods: Studies describing the epidemiology and economic burden from national cohorts, any economic models, or any humanist
Autor:
Abdalla, Aly, Courtney, Johnson, Yunes, Doleh, Viktor, Chirikov, Marc, Botteman, Rahul, Shenolikar, Arif, Hussain
Publikováno v:
J Clin Pathw
BACKGROUND: Urothelial carcinoma (UC) is generally diagnosed early and may incur significant lifetime costs. This study estimated, from the payer’s perspective, the lifetime costs among patients diagnosed with UC according to stage at diagnosis. ME
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 10, Pp 3463-3476 (2020)
Cancer Medicine, Vol 9, Iss 10, Pp 3463-3476 (2020)
Background Pancreatic cancer represents the third leading cause of US cancer deaths, with median survival
In a real‐world retrospective study, 57% of patients with advanced metastatic pancreatic cancer did not receive chemotherapy. Total healt
In a real‐world retrospective study, 57% of patients with advanced metastatic pancreatic cancer did not receive chemotherapy. Total healt
Autor:
Petros Grivas, Yunes Doleh, Mei Sheng Duh, Maral DerSarkissian, François Laliberté, Rahul Shenolikar
Publikováno v:
Future oncology (London, England). 15(33)
Aim: To estimate incremental costs and healthcare resource utilization (HRU) associated with select severe adverse events (AEs) and AEs of any severity in patients with metastatic urothelial carcinoma receiving first-line (1L) therapy. Materials & me
Autor:
Shilpa Gupta, Yunes Doleh, Brian Seal, Marija Tesic-Schnell, Anna Boudoures, Martine C Maculaitis, Andrew Bernstein, Emily Mulvihill
Publikováno v:
Journal of Clinical Oncology. 38:e19184-e19184
e19184 Background: The role of PD-L1 testing in locally advanced (LA) or metastatic urothelial carcinoma (mUC) is not currently well-defined, except in cisplatin-ineligible patients (pts). IMVigor130 trial data are the first to suggest cisplatin-elig